Skip to main content
. 2017 Oct 9;7:12875. doi: 10.1038/s41598-017-13166-w

Figure 5.

Figure 5

Abundance changes along the time course of ABA treatment for quercetin and quercetin derivatives (A), non-quercetin flavonoids (B), and glucosinolates (C). Metabolites 1–22 are: 1: quercetin-3-(6″-malonyl)-glucoside; 2: quercetin; 3: quercetin-3-arabinoside; 4: quercetin-3,4′-O-di-beta-glucopyranoside; 5: quercetin-4′-glucoside; 6: myricetin-3-galactoside; 7: kaempferol; 8: kaempferol-3-O-glucoside; 9: cyanidin-3,5-di-O-glucoside; 10: hesperetin; 11: isosakuranetin-7-O-neohesperidoside; 12: cyanidin-3-sophoroside; 13: hesperidin; 14: naringin; 15: cyanidin-3-O-galactoside; 16: 3-hydroxy-3′,4′,5′-trimethoxyflavone; 17: myricetin; 18: 7-methylthioheptyl glucosinolate; 19: 8-methylthiooctyl glucosinolate; 20: (2 R)−2-hydroxy-2-phenethylglucosinolate; 21: 4-methylsufinyl-3-butenyl glucosinolate. Solid data points indicate statistically significant changes upon ABA treatment (Student’s t test; p value < 0.05) compared to 0 min data.